Clinical Trials Browser

Phase 2 × Active not recruiting × Abiraterone Acetate × Clear all

NCT03419234 2026-03-12

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Phase 2 Active not recruiting

223 enrolled 14 charts

Prostatic Neoplasms

NCT02703623 2026-03-06

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04748042 2026-03-06

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT01786265 2026-02-20

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03902951 2026-02-05

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04267887 2026-01-20

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02949284 2026-01-07

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Phase 2 Active not recruiting

Stage II Prostate Adenocarcinoma

NCT05689021 2026-01-07

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03431350 2025-12-23

QUEST

Phase 2 Active not recruiting

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT03436654 2025-11-28

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03012321 2025-10-21

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03821792 2025-10-10

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03141671 2024-05-14

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Phase 2 Active not recruiting

Prostatic Neoplasms